title: Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis.
abstract: Silicosis is an inflammatory lung disease induced by the inhalation of silica-containing dust particles. There is conflicting data on whether patients with silicosis are more susceptible to lung cancer induced by cigarette smoke. To examine this issue experimentally, a model was developed in which one of the most abundant and potent carcinogens present in cigarette smoke [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)] was administered to mice at the peak of silica-induced pulmonary inflammation. Results show that the incidence of lung tumors in silicotic mice treated with NNK was significantly increased compared with mice exposed to silica or NNK alone. Synthetic oligonucleotides (ODN) containing repetitive TTAGGG motifs can block pathologic inflammation. We therefore examined whether treatment with these suppressive (Sup) ODN could block silica-induced pulmonary inflammation and thereby reduce susceptibility to lung cancer. Results show that Sup (but not control) ODN inhibit pulmonary fibrosis and other inflammatory manifestations of chronic silicosis. Of greater import, Sup ODN reduced lung tumor incidence and multiplicity in silicotic mice exposed to NNK. These findings establish an experimental model for examining the role of silicotic inflammation in cancer susceptibility and demonstrate that Sup ODN represent a novel therapy for chronic silicosis.
authors.affiliation: Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
authors.forename: Christian
authors.initials: C
authors.lastname: Bode
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kinjo
authors.forename: W Gregory
authors.initials: WG
authors.lastname: Alvord
authors.forename: Dennis M
authors.initials: DM
authors.lastname: Klinman
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015415:Biomarkers; D004195:Disease Models, Animal; D004198:Disease Susceptibility; D005260:Female; D015870:Gene Expression; D006801:Humans; D053583:Interleukin-1beta / Q000235:genetics / Q000378:metabolism; D008175:Lung Neoplasms / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D009602:Nitrosamines / Q000009:adverse effects; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000494:pharmacology*; D011014:Pneumonia / Q000150:complications / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012822:Silicon Dioxide / Q000009:adverse effects; D012829:Silicosis / Q000150:complications* / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D053583:Interleukin-1beta; D009602:Nitrosamines; D009838:Oligodeoxyribonucleotides; D012333:RNA, Messenger; D012822:Silicon Dioxide; C016583:4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone